Immuneering Corporation
IMRX
Jodie situation report
Immuneering Corporation's current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 6 directly disclosed connections are confirming.
- IMRX's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if IMRX's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind IMRX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
REGNRegeneron Pharmaceuticals, Inc.partnerMar 6, 2026 ▾
“11 Table of Contents In February 2025, we announced entry into a clinical supply agreement with Regeneron Pharmaceuticals for its anti-PD-1 therapy, Libtayo® (cemiplimab), which intends to support the evaluation of atebimetinib in combination with Libtayo in…”
LLYEli Lilly and CompanypartnerMar 6, 2026 ▾
“In August 2025, we announced a clinical supply agreement with Eli Lilly and Company for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982), which intends to support the evaluation of atebimetinib in combination with olomorasib in a planned clin…”
AZNAstraZeneca PLCpartnerMar 6, 2026 ▾
“Our leadership team brings together expertise across translational bioinformatics, preclinical and clinical development, and pharmaceutical business operations in oncology and includes individuals with extensive experience at some of the leading pharmaceutica…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 5 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
IMRX is currently a Leader in the organic co-movement group Oncology Clinical Trials. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for IMRX; it is not active in the latest market snapshot.